"Spike" Well-known Trademark Rewards
Release time:
2020-08-14
Jinhua City Held Trademark Brand Conference
"Peak" Well-known Trademark Awarded
News 5# October 27 , Jinhua City Held Trademark Brand Conference. Jianfeng Pharmaceutical Company was recognized as a well-known trademark by the State Administration for Industry and Commerce for its "Jianfeng" trademark in 2016 , and won a special reward fund of 120 yuan at the conference. Yu Jianhong, general manager of the group company, as the only representative of the enterprise, spoke at the meeting to share the experience of brand building.
In recent years, the Jinhua Municipal Government has attached great importance to trademark brand building, and has successively issued "Opinions on the In-depth Implementation of Trademark Brand Strategy", "Jinhua Urban Brand Development Support and Incentive Measures", and "Jinhua Trademark Development" A series of policy documents such as the "Five-Year Plan" have incorporated the promotion of trademark brand strategy into the overall framework of government work. This year is also the third consecutive year that Jinhua has held a city-wide trademark brand conference, which shows Jinhua's firm determination to promote the construction of "brand Jinhua. The meeting stressed that it is necessary to organically combine the in-depth promotion of trademark brand strategy with the promotion of supply-side structural reform, speed up the development of trademark brands, stimulate the power of enterprises to create, use and protect brands, and speed up the promotion of Jinhua from a big brand city to a strong brand city.
Peak has always attached great importance to trademark management and brand creation. As early as 1980 , the "Peak" brand cement trademark was registered and used. In 1993 , the public solicitation of trademark patterns and advertising slogans also caused a sensation both inside and outside the province. At present, Jianfeng has a total of 223 registered trademarks including 1 well-known trademarks in China, 3 provincial famous trademarks and 5 Jinhua municipal famous trademarks, of which "Jianfeng" trademark has been continuously recognized as a famous trademark in Zhejiang Province since 1992 ; the peak graphic logo and peak text logo of the subsidiary Jianfeng Pharmaceutical Co., Ltd. were recognized as famous trademarks in Zhejiang Province in 2013 1 , and the "Jianfeng" trademark in 2016 9 was recognized as "China Famous Trademark" by the State Administration for Industry and Commerce ". In the same year, Jianfeng Group was included in the second batch of "three" project pilot cultivation enterprises in Zhejiang Province and Jinhua trademark brand demonstration enterprises. For more than 30 years, through the creation of famous and well-known trademarks, the company has greatly improved the status of its products, established a good image of the company, and enhanced its ability to ensure the sustainable and healthy development of the company. The
meeting commended Jianfeng Pharmaceutical and other enterprises that won the recognition of China's well-known trademarks in 2016 . Jianfeng Pharmaceutical is also the only enterprise in Jinhua Development Zone that won this honor in 2016 . And to the provincial and municipal famous trademark enterprise representatives, provincial and municipal trademark brand demonstration villages and towns (streets), demonstration enterprises and brand base representatives; representatives of Yongkang Municipal Government, Municipal Construction Bank, Pan'an County Market Supervision Bureau and Jianfeng Group made exchange speeches.
As the only outstanding enterprise representative for brand creation, General Manager Yu Jianhong has improved the organization and strengthened trademark management. Committed to innovation to build a solid foundation for brand building; Pay close attention to quality and enhance brand reputation; Pay attention to market construction and strengthen brand influence; Pay attention to social effects and enrich brand connotation, and share the experience of peak brand construction. (Zhang Mingyin Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page